{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:58:41Z","timestamp":1773194321841,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Green cross"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Varicella-zoster virus (VZV) is a pathogen that causes chickenpox and shingles in humans. Different types of the varicella vaccines derived from the Oka and MAV\/06 strains are commercially available worldwide. Although the MAV\/06 vaccine was introduced in 1990s, little was known about immunological characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, we evaluated B and T cell immune response in animals inoculated with the Oka and MAV\/06 vaccines as well as a new formulation of the MAV\/06 vaccine. A variety of test methods were applied to evaluate T and B cell immune response. Plaque reduction neutralization test (PRNT) and fluorescent antibody to membrane antigen (FAMA) assay were conducted to measure the MAV\/06 vaccine-induced antibody activity against various VZVs. Glycoprotein enzyme-linked immunosorbent assay (gpELISA) was used to compare the degree of the antibody responses induced by the two available commercial VZV vaccines and the MAV\/06 vaccine. Interferon-gamma enzyme-linked immunosorbent spot (IFN-\u03b3 ELISpot) assays and cytokine bead array (CBA) assays were conducted to investigate T cell immune responses. Antibodies induced by MAV\/06 vaccination showed immunogenicity against a variety of varicella-zoster virus and cross-reactivity among the virus clades.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>It is indicating the similarity of the antibody responses induced by commercial varicella vaccines and the MAV\/06 vaccine. Moreover, VZV-specific T cell immune response from MAV\/06 vaccination was increased via Th1 cell response. MAV\/06 varicella vaccine induced both humoral and cellular immune response via Th1 cell mediated response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-022-00503-6","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T16:05:42Z","timestamp":1654272342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunological characteristics of MAV\/06 strain of varicella-zoster virus vaccine in an animal model"],"prefix":"10.1186","volume":"23","author":[{"given":"Duckhyang","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younchul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyojung","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"503_CR1","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","volume":"1","author":"AA Gershon","year":"2015","unstructured":"Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Prim. 2015;1:15016.","journal-title":"Nat Rev Dis Prim"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","volume":"12","author":"L Zerboni","year":"2014","unstructured":"Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol. 2014;12:197\u2013210.","journal-title":"Nat Rev Microbiol"},{"key":"503_CR3","first-page":"111","volume":"24","author":"K-K Hwang","year":"1994","unstructured":"Hwang K-K, Woo G-J, Chun B-H, Park S-Y, Moon H-M. Development of a Live Attenuated Varicella Vaccin (MAV\/06): Immunological and Clinical Responses in Healty Persons. J Korean Soc Virol. 1994;24:111\u201322.","journal-title":"J Korean Soc Virol"},{"key":"503_CR4","unstructured":"Takahashi M. Development and characterization of a live varicella vaccine (Oka strain). Biken J. 1984."},{"key":"503_CR5","unstructured":"Takahashi M. Development of a live varicella vaccine--past and future. Jpn J Infect Dis. 2000."},{"key":"503_CR6","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/j.vaccine.2016.04.059","volume":"34","author":"T Ozaki","year":"2016","unstructured":"Ozaki T, Asano Y. Development of varicella vaccine in Japan and future prospects. Vaccine. 2016;34:3427\u201333.","journal-title":"Vaccine"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1517\/14712598.2013.830101","volume":"13","author":"HQ Doan","year":"2013","unstructured":"Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK. Zostavax\u202f: a subcutaneous vaccine for the prevention of herpes zoster. Expert Opin Biol Ther. 2013;13:1467\u201377.","journal-title":"Expert Opin Biol Ther"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1086\/653605","volume":"51","author":"MN Oxman","year":"2010","unstructured":"Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197\u2013213.","journal-title":"Clin Infect Dis"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1586\/14760584.5.4.431","volume":"5","author":"M Holodniy","year":"2006","unstructured":"Holodniy M. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines. 2006;5:431\u201343.","journal-title":"Expert Rev Vaccines"},{"key":"503_CR10","doi-asserted-by":"crossref","unstructured":"James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Annals of Pharmacotherapy. 2018.","DOI":"10.1177\/1060028018758431"},{"key":"503_CR11","first-page":"341","volume":"342","author":"A Weinberg","year":"2010","unstructured":"Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341\u201357.","journal-title":"Curr Top Microbiol Immunol"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825\u201335.","journal-title":"J Infect Dis"},{"issue":"6 Suppl 2","key":"503_CR13","first-page":"S13","volume":"109","author":"MN Oxman","year":"2009","unstructured":"Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109(6 Suppl 2):S13\u20137.","journal-title":"J Am Osteopath Assoc"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1128\/JVI.06623-11","volume":"86","author":"A Weinberg","year":"2012","unstructured":"Weinberg A, Huang S, Song L-Y, Fenton T, Williams P, Patterson J, et al. Immune correlates of herpes zoster in HIV-infected children and youth. J Virol. 2012;86:2878\u201381.","journal-title":"J Virol"},{"key":"503_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002367","volume":"7","author":"K Haberthur","year":"2011","unstructured":"Haberthur K, Engelmann F, Park B, Barron A, Legasse A, Dewane J, et al. CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog. 2011;7: e1002367.","journal-title":"PLoS Pathog"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/171.1.13","volume":"171","author":"S Nader","year":"1995","unstructured":"Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995;171:13\u20137.","journal-title":"J Infect Dis"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/infdis\/165.1.119","volume":"165","author":"A Wilson","year":"1992","unstructured":"Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992;165:119\u201326.","journal-title":"J Infect Dis"},{"key":"503_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1086\/517426","volume":"177","author":"L Zerboni","year":"1998","unstructured":"Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis. 1998;177:1701\u20134.","journal-title":"J Infect Dis"},{"key":"503_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/infdis\/137.5.531","volume":"137","author":"AM Arvin","year":"1978","unstructured":"Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis. 1978;137:531\u201340.","journal-title":"J Infect Dis"},{"key":"503_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.meegid.2010.08.014","volume":"11","author":"J Schmidt-Chanasit","year":"2011","unstructured":"Schmidt-Chanasit J, Sauerbrei A. Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol. 2011;11:1\u201310.","journal-title":"Infect Genet Evol"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/JVI.06233-11","volume":"86","author":"R Zell","year":"2012","unstructured":"Zell R, Taudien S, Pfaff F, Wutzler P, Platzer M, Sauerbrei A. Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination. J Virol. 2012;86:1608\u201322.","journal-title":"J Virol"},{"issue":"Suppl 1","key":"503_CR22","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/jmv.10319","volume":"70","author":"W Barrett-Muir","year":"2003","unstructured":"Barrett-Muir W, Scott FT, Aaby P, John J, Matondo P, Chaudhry QL, et al. Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J Med Virol. 2003;70(Suppl 1):S42\u20137.","journal-title":"J Med Virol"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1086\/344228","volume":"186","author":"M Quinlivan","year":"2002","unstructured":"Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT, et al. The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis. 2002;186:888\u201394.","journal-title":"J Infect Dis"},{"key":"503_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1586\/erv.11.93","volume":"10","author":"M Quinlivan","year":"2011","unstructured":"Quinlivan M, Breuer J, Schmid DS. Molecular studies of the Oka varicella vaccine. Expert Rev Vaccines. 2011;10:1321\u201336.","journal-title":"Expert Rev Vaccines"},{"key":"503_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/1743-422X-8-547","volume":"8","author":"JI Kim","year":"2011","unstructured":"Kim JI, Jung GS, Kim YY, Ji GY, Kim HS, Wang WD, et al. Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax. Virol J. 2011;8:547.","journal-title":"Virol J"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.virusres.2017.12.004","volume":"245","author":"SC Kim","year":"2018","unstructured":"Kim SC, Won YH, Park JS, Jeon JS, Ahn JH, Song MJ, et al. Vaccine-type mutations identified in Varicella zoster virus passaged in cell culture. Virus Res. 2018;245:62\u20138.","journal-title":"Virus Res"},{"key":"503_CR27","doi-asserted-by":"crossref","unstructured":"Kim MH, Jeon JS, Kim IK, Park JS, Park H, Shin OS, et al. Characterization and phylogenetic analysis of Varicella-zoster virus strains isolated from Korean patients. J Microbiol. 2017.","DOI":"10.1007\/s12275-017-7171-3"},{"key":"503_CR28","first-page":"109","volume":"24","author":"M Takayama","year":"1981","unstructured":"Takayama M, Oya A. A single serum dilution method for the quantitation of neutralizing antibodies to varicella-zoster virus. Biken J. 1981;24:109\u201318.","journal-title":"Biken J"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","volume":"130","author":"V Williams","year":"1974","unstructured":"Williams V, Gershon A, Brunell PA. Serologic Response to Varicella-Zoster Membrane Antigens Measured by Indirect Immunofluorescence. J Infect Dis. 1974;130:669\u201372.","journal-title":"J Infect Dis"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1128\/CVI.05130-11","volume":"18","author":"MM Lafer","year":"2011","unstructured":"Lafer MM, Weckx LY, de Moraes-Pinto MI, Garretson A, Steinberg SP, Gershon AA, et al. Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus. Clin Vaccine Immunol. 2011;18:1194\u20137.","journal-title":"Clin Vaccine Immunol"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1128\/CVI.00183-12","volume":"19","author":"A Sauerbrei","year":"2012","unstructured":"Sauerbrei A, Sch\u00e4fler A, Hofmann J, Schacke M, Gruhn B, Wutzler P. Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol. 2012;19:1261\u20138.","journal-title":"Clin Vaccine Immunol"},{"key":"503_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/imr.12099","volume":"255","author":"B Pulendran","year":"2013","unstructured":"Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. Immunity to viruses: learning from successful human vaccines. Immunol Rev. 2013;255:243\u201355.","journal-title":"Immunol Rev"},{"issue":"Suppl","key":"503_CR33","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1086\/522123","volume":"197","author":"AM Arvin","year":"2008","unstructured":"Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl):S58-60.","journal-title":"J Infect Dis"},{"key":"503_CR34","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","volume":"112","author":"J Zhu","year":"2008","unstructured":"Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557\u201369.","journal-title":"Blood"},{"key":"503_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/925135","volume":"2012","author":"RV Luckheeram","year":"2012","unstructured":"Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012;2012: 925135.","journal-title":"Clin Dev Immunol"},{"key":"503_CR36","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1016\/j.vaccine.2011.03.054","volume":"29","author":"A Sauerbrei","year":"2011","unstructured":"Sauerbrei A, Stefanski J, Gruhn B, Wutzler P. Immune response of varicella vaccinees to different varicella-zoster virus genotypes. Vaccine. 2011;29:3873\u20137.","journal-title":"Vaccine"},{"issue":"Supplement 1","key":"503_CR37","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1093\/infdis\/166.Supplement_1.S63","volume":"166","author":"AA Gershon","year":"1992","unstructured":"Gershon AA, LaRussa P, Hardy L, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis. 1992;166(Supplement 1):S63\u20138.","journal-title":"J Infect Dis"},{"key":"503_CR38","doi-asserted-by":"crossref","unstructured":"Chalmin F, Humblin E, Ghiringhelli F, V\u00e9gran F. Transcriptional programs underlying Cd4 T cell differentiation and functions. In: International Review of Cell and Molecular Biology. 2018. p. 1\u201361.","DOI":"10.1016\/bs.ircmb.2018.07.002"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-022-00503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T16:07:28Z","timestamp":1654272448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-022-00503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s12865-022-00503-6","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All experiments including the procedures used and the care of animals were approved by the Institutional Animal Care and Use Committee in GC Biopharma Corp (approval No. 2018002). In addition, we confirm that all methods were carried out in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals and the Guidelines and Policies for Rodent Experiments provided by the IACUC (Institutional Animal Care and Use Committee), and all methods are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Shin DH, Shin YC, Kim EM, Nam HJ, Lee JW employees of the GC group of companies. Involvement of GC employees did not compromise the scientific integrity of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}